Skip to main content

Normal pressure hydrocephalus associated with COVID-19 infection: a case report



COVID-19 is a pandemic disease responsible for many deaths worldwide. Many neurological manifestations have been described. We report a case of normal pressure hydrocephalus (NPH) 2 months after acute COVID19 infection, in a patient without other risk factors.

Case presentation

A 45-year-old male patient presented an 8-month history of progressive gait disorder and cognitive impairment after being hospitalized for SARS-CoV-2 infection. Magnetic resonance imaging (MRI) was compatible with NPH. A spinal tap test was positive and there was progressive improvement after shunting, with complete resolution of symptoms.


Other infections such as syphilis, cryptococcosis and Lyme disease have been associated with NPH. Possible mechanisms for NPH after COVID include disruption of choroid plexus cells by direct viral invasion or as a result of neuroinflammation and cytokine release and hypercoagulability leading to venous congestion and abnormalities of CSF flow. Given the significance of NPH as a cause of reversible dementia, it is important to consider the possibility of a causal association with COVID19 and understand the mechanisms behind this association.

Peer Review reports


COVID-19 is a pandemic disease caused by an RNA virus named SARS-CoV-2 and is primarily a respiratory disease involving lower and upper airways, although many neurologic manifestations have been described [1]. Similarly, to what has been reported with other coronaviruses, such as MERS-CoV and SARS-CoV-1, this pathogen has shown possibly neurotropic and neuroinvasive properties resulting in a wide range of neurologic manifestations [1].

Normal pressure hydrocephalus (NPH) is a condition characterized by a triad of cardinal symptoms composed by gait disorder, urinary incontinence and cognitive decline associated with dilated ventricles, in the absence of intracranial hypertension [2].

Herein, we report a case of Normal Pressure Hydrocephalus occurring two months after acute COVID19 infection.

Case presentation

A 45-year-old man presented with a history of imbalance and progressive gait disorder for the last 8 months, associated with memory impairment. He had a previous history of bipolar disorder and type II diabetes mellitus and reported a COVID19 infection 2 months before initial presentation of neurologic symptoms.

Initial symptoms of SARS-Cov-2 infection were fever, anosmia, dysgeusia and anorexia. A real-time reverse-transcriptase-polymerase-chain-reaction assay (Allplex™ SARS-CoV-2 Assay—N/RdRP/S genes) confirmed the diagnosis. Hospitalization for seven days and oxygen via nasal cannula were necessary. At discharge, he was able to walk unassisted.

Two months after acute COVID19 infection the patient started a progressive gait disorder, complaining that he felt like his feet were glued to the ground. After a few weeks, he started forgetting recent facts and his family complained of excessive daytime sleepiness and blunted affect. He progressed to executive dysfunction and difficulty in performing his labor activities. There was no history of head trauma, subarachnoid hemorrhage (SAH) or meningitis. There was also no family history of neurologic diseases.

Neurologic examination revealed short-term memory loss, slow processing speed, inattention, difficulty in planning and executive dysfunction. A mild tetraparesis was also perceived, with brisk deep tendon reflexes in four limbs. There was no clonus and flexor plantar responses were observed. There was mild rigidity of the upper limbs, without cogwheeling. Gait was slow and magnetic, with short steps, feet close to the ground and postural instability.

Laboratory evaluation did not reveal any abnormalities (Table 1). Complete blood count, renal function, liver enzymes and thyroid hormones were normal. Serology was negative for Syphilis and HIV. Vitamin B12 levels were also normal.

Table 1 Laboratory and cerebrospinal fluid analysis in a patient with normal pressure hydrocephalus after COVID19

Brain magnetic resonance imaging (MRI) disclosed moderately dilated supratentorial ventricular system with callosal angle reduction and aqueduct flow-void (Fig. 1). A high-volume (40 ml) lumbar tap test was performed and revealed an opening pressure of 100mmH2O (normal range < 200 mmH2O). There was marked improvement of gait and balance after the procedure—10 m timed up and go (TUG) before the procedure of 18.4 s (32 steps) and after the procedure of 16.7 s (27 steps). CSF analysis was entirely normal (Table 1).

Fig. 1
figure 1

Brain MRI in a patient with normal pressure hydrocephalus after COVID19 infection showing: A Axial T2-weighted image with dilated lateral ventricles, B coronal T1-weighted image depicting acute callosal angle and upward bowing of the corpus callosum and C sagittal T1-weighted image showing normal infratentorial ventricular compartment

A diagnosis of Normal Pressure Hydrocephalus was made and a ventriculoperitoneal shunt was placed without adverse events. Thirty days later there was significant improvement of gait, now presenting normal speed and step length. Cognitive functions also improved substantially, and he returned to his previous work activities. The patient reports that his ability to perform his labor activities is normal and is very pleased with his clinical outcome.

Discussion and conclusion

We have described a previously healthy patient who developed NPH two months after COVID19 infection, presenting with gait apraxia and cognitive impairment.

Normal pressure hydrocephalus has been classified as idiopathic or secondary [3]. Many diseases have been implicated in its etiology, such as subarachnoid hemorrhage (SAH), traumatic brain injury (TBI), meningitis, stroke and intracranial neoplasms [3]. Some specific infectious diseases have also been reported as possible etiologies for NPH, including Lyme disease, neurosyphilis and cryptococcosis [4]. There are reports of hydrocephalus following SAH in patients with concomitant coronavirus infections [5, 6], but as far as we know this is the first case of NPH associated with COVID-19 infection without preceding SAH or stroke.

The main theory to explain central nervous system (CNS) invasion is that SARS-CoV-2 probably enters olfactory nerves through interaction of the viral S protein with the Angiotensin Converting Enzyme 2 (ACE2) receptor on olfactory epithelium [1]. The spatial distribution of ACE2 receptors in the CNS was studied using brain transcriptome data banks and high concentrations of these receptors were found in the choroid plexus of lateral ventricles suggesting that the choroid plexus could be a pathway for SARS-CoV-2 to enter the CNS [7]. It is possible that this interaction between the virus and the choroid plexus could alter the dynamics of CSF flow, contributing to NPH. An animal model study of hydrocephalus after SAH has demonstrated that inflammation of choroid plexus cells marked by increase in NF-kB results in dysfunction of these barrier cells leading to production of increased abnormal protein-rich CSF, and consequentially in hydrocephalus due to excess CSF production [8].

Many neuroinvasive viruses such influenza A and B can initially trigger an innate immune response by activating microglia [9]. Microglia also activate astrocytes that can modulate the recruitment and activation of additional microglial and other immunocompetent cells [10]. Microglial and astrocyte activation as well as massive cytokine release might lead to inflammation of arachnoid villi resulting in fibrosis and adhesion of these structures, reduction in CSF reabsorption, and consequently to hydrocephalus [11]. Another possible factor in the etiology of COVID19-associated NPH is a hypercoagulable state induced by the systemic response to SARS-CoV-2 [12], which could lead to venous congestion and CSF flow abnormalities [11].

In a series of patients with persistent headache after COVID-19 infection 84.6% had increased intracranial pressure (ICP) in the absence of meningitis [13]. It is possible that some of these patients with initially elevated ICP might progress to NPH over time as the CSF compartment rearranges itself in a larger volume to maintain physiologic ICP according to Laplace’s law [14].

Unfortunately, we were not able to test CSF for COVID antibodies due to local technical limitations. In a recent study of 8 patients with COVID-associated encephalopathy (ref [1]) all patients had positive anti-SARS-CoV-2 antibodies in CSF, but only 4 of them (50%) had high titers comparable to blood titers. Among these 4 patients, only 1 had intrathecal anti-SARS-CoV-2 IgG synthesis, the remainder had disruption of the blood–brain-barrier. As such, it is still unclear whether specific anti-SARS-CoV-2 antibodies play a role in neurologic manifestations associated with COVID, or if blood–brain-barrier dysfunction with cytokine influx is the main component in such manifestations [15].

We have described the first case of normal pressure hydrocephalus possibly associated with COVID19 infection. Although pathophysiological mechanisms are still unclear and we cannot be certain that NPH occurred because of COVID19, there was a clear temporal correlation, and the patient did not have other risk factors for NPH. Given the significance of this condition as a cause of reversible dementia, it is important to consider the possibility of a causal association with COVID19. More reports are necessary to confirm this association and clarify its mechanisms.

Availability of data and materials

All data generated or analysed during this study are included in this published article.



Angiotensin converting enzyme 2


Central nervous system


Intracranial pressure


Magnetic resonance imaging


Normal pressure hydrocephalus


Subarachnoid hemorrhage


Traumatic brain injury


  1. Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol. 2020;77(8):1018.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Gallia GL, Rigamonti D, Williams MA. The diagnosis and treatment of idiopathic normal pressure hydrocephalus. Nat Rev Neurol. 2006;2(7):375–81.

    Article  Google Scholar 

  3. Daou B, Klinge P, Tjoumakaris S, Rosenwasser RH, Jabbour P. Revisiting secondary normal pressure hydrocephalus: does it exist? A review. FOC. 2016;41(3):E6.

    Article  Google Scholar 

  4. Abdool K, Seegobin K, Ramcharan K, Alexander A, Julien-Legen L, Giddings SL, et al. Neurosyphilis with normal pressure hydrocephalus and dementia paralytica: serial clinical, laboratory and radiological correlations in the 21st century. Neurol Int. 2016.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Al Saiegh F, Ghosh R, Leibold A, Avery MB, Schmidt RF, Theofanis T, et al. Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke. J Neurol Neurosurg Psychiatry. 2020;91(8):846–8.

    Article  PubMed  Google Scholar 

  6. Weisbrod L, Davidson C, Gard A, Surdell D. Low-pressure hydrocephalus in spontaneous angiogram-negative subarachnoid hemorrhage following COVID-19 infection. Cureus. 2021;13:7.

    Google Scholar 

  7. Chen R, Wang K, Yu J, Howard D, French L, Chen Z, et al. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains. Front Neurol. 2021;20(11): 573095.

    Article  Google Scholar 

  8. Simard PF, Tosun C, Melnichenko L, Ivanova S, Gerzanich V, Simard JM. Inflammation of the choroid plexus and ependymal layer of the ventricle following intraventricular hemorrhage. Transl Stroke Res. 2011;2(2):227–31.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Tse H, To KKW, Wen X, Chen H, Chan K-H, Tsoi H-W, et al. Clinical and virological factors associated with viremia in pandemic influenza A/H1N1/2009 virus infection. PLoS ONE. 2011;6(9):e22534.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Liu W, Tang Y, Feng J. Cross talk between activation of microglia and astrocytes in pathological conditions in the central nervous system. Life Sci. 2011;89(5–6):141–6.

    Article  CAS  PubMed  Google Scholar 

  11. Kibler RF, Couch RSC, Crompton MR. Hydrocephalus in the adult following spontaneous subarachnoid hæmorrhage. Brain. 1961;84(1):45–61.

    Article  CAS  PubMed  Google Scholar 

  12. Wichmann D, Sperhake J-P, Lütgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020;173(4):268–77.

    Article  PubMed  Google Scholar 

  13. Silva MTT, Lima MA, Torezani G, Soares CN, Dantas C, Brandão CO, et al. Isolated intracranial hypertension associated with COVID-19. Cephalalgia. 2020;40(13):1452–8.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Hakim S, Adams RD. The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. J Neurol Sci. 1965;2(4):307–27.

    Article  CAS  PubMed  Google Scholar 

  15. Alexopoulos H, Magira E, Bitzogli K, et al. Anti–SARS-CoV-2 antibodies in the CSF, blood–brain barrier dysfunction, and neurological outcome: studies in 8 stuporous and comatose patients. Neurol Neuroimmunol Neuroinflamm. 2020;7(6): e893.

    Article  PubMed  PubMed Central  Google Scholar 

Download references


Not applicable.


One of the authors (Pedro Braga Neto) received funding from the Brazilian National Council for Scientific and Technological Development (CNPq) as research grant funding. We also acknowledge the Brazilian Funding Grant Number 88881.505364/2020-01 from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES).

Author information

Authors and Affiliations



Conception of the work—TMFV, PRN and JDNC. Drafting the work—TMFV, PRN, GMF. Acquisition of the data—TMFV, PRN, MASN, MLPS and ASV. Analysis and interpretation of data for the work –TMFV, PRN, PBN and MASN. Design of the work—PRN, PBN and MASN. Revising the work critically—PRN, PBN and MASN. Final approval of the version to be published and agreement to be accountable for all aspects of the work—all authors.

Corresponding author

Correspondence to Pedro Braga-Neto.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Competing interests

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vasconcelos, T.M.F., Nóbrega, P.R., Ferreira, G.M. et al. Normal pressure hydrocephalus associated with COVID-19 infection: a case report. BMC Infect Dis 22, 216 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: